Table 4.

Adjusted odds ratios of the quality of the therapeutic pathway and of short-term outcomes, and adjusted hazard ratios of disease free- and overall survival by diagnostic modality, with 95% confidence intervals (CI).

Category	Outcome	Adjusted1 Odds Ratio (SD vs. NSD) (95% CI)	p-value
1. Quality of the therapeutic pathway	1.1: Time between diagnosis and treatment ≤ 30 days	0.55 (0.40–0.77)1	0.0004
	1.2: Time between surgery and chemotherapy < 8 weeks	2.20 (1.21–4.03)2	0.01
	1.3: Length of postoperative hospital stay ≤ 12 days	1.16 (0.70–1.93)2	0.56
2. Short-term outcomes	2.1: 30 days readmission	0.65 (0.32–1.32)3	0.23
	2.2: 30 days surgery- related readmission	0.77 (0.35–1.66)3	0.51
	2.3: 30 days reintervention	0.72 (0.40–1.29)3	0.27
	2.4: 30 days surgery- related reintervention	0.84 (0.35–2.00)3	0.69
	2.5: EBL >500 ml	0.31 (0.12–0.80)3	0.01
	2.6: Readmission due to surgical complications	0.96 (0.32–3.02)3	0.98
	2.7: Readmission due to medical complications	1.15 (0.36–3.65)3	0.81
	2.8: Reinterventions due to surgical complications	1.87 (0.72–4.84)3	0.46
	2.9: Reinterventions due to medical complications	0.84 (0.24–2.95)3	0.78
	2.10: Surgical complications	0.76 (0.44–1.34)3	0.34
	2.11: Medical complications	1.18 (0.57–2.44)3	0.66
	2.12: Complications (surgical or medical)	0.87 (0.53–1.41)3	0.56
3. Survival	3.1: Disease Free Survival	0.40 (0.22–0.73)4	0.0029
	3.2: Overall Survival	0.25 (0.12–0.51)4	0.0002

¹According to logistic regression adjusted by gender, age, CRC stage at diagnosis, cancer site, surgery unit, and comorbidity.

²According to logistic regression adjusted by gender, age, CRC stage at diagnosis, cancer site, surgery unit, comorbidity, surgical approach, stoma creation, and neoadjuvant treatment.

³According to logistic regression adjusted by gender, age, CRC stage at diagnosis, cancer site, surgery unit, comorbidity, surgical approach, stoma creation, neoadjuvant treatment, resection margin, lymphatic invasion, vascular invasion, perineurial invasion, and grading.

⁴According to Cox regression model adjusted by gender, age, CRC stage at diagnosis, cancer site, surgery unit, comorbidity, surgical approach, stoma creation, neoadjuvant treatment, resection margin, lymphatic invasion, vascular invasion, perineurial invasion, grading, and adjuvant treatment.

SD, screen detected; NSD, non screen detected; EBL, Estimated Blood Loss.